Spectral Medical (EDT) AI Stock Analysis

• Market Cap: $230.94M
• Dividend Yield: N/A
• Average Volume (3M): 53.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: 43.05%
• EPS Growth: 2.14%
• Country: CA
• Employees: 29
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.04
• Shares Outstanding: 285,117,220
• 10 Day Avg. Volume: 22,746
• 30 Day Avg. Volume: 53,801
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Spectral Medical's overall stock score reflects significant financial challenges, with persistent losses and negative cash flows weighing heavily on its outlook. However, positive momentum from technical indicators and promising corporate events provide optimism. Valuation remains weak due to the lack of profitability.

Spectral Medical Business Overview & Revenue Model

Company Description

Spectral Medical Inc. (EDT) is a medical technology company operating primarily in the healthcare sector. The company focuses on developing and commercializing innovative products aimed at improving patient outcomes in critical care. Its flagship product, the Toraymyxin PMX-20R, is an extracorporeal hemoperfusion device aimed at treating patients with endotoxemia and septic shock. Spectral Medical is dedicated to advancing its therapeutic solutions and enhancing patient care through ongoing research and development.

How the Company Makes Money

Spectral Medical makes money through the sale and distribution of its medical devices, primarily the Toraymyxin PMX-20R, to hospitals and healthcare facilities. The company generates revenue by supplying these devices for use in critical care settings where patients with endotoxemia and septic shock are treated. Additionally, Spectral Medical may engage in strategic partnerships and collaborations with other healthcare organizations to expand its market reach and enhance its product offerings. Revenue is also supported by ongoing research and development efforts which may lead to the introduction of new products and enhancements to existing solutions.

Spectral Medical Financial Statement Overview

Summary

Spectral Medical faces significant financial challenges, characterized by consistent losses and negative cash flows. Increasing total debt and negative equity raise concerns about financial stability and solvency. The company's ability to improve its financial health is uncertain without a strategic turnaround.

Income Statement

Revenue has shown volatility with a decline from 2019 to 2020, followed by fluctuations in subsequent years. The company has consistently reported negative net income, leading to negative net profit margins. EBITDA margin is also negative, indicating operational challenges. Despite a slight increase in gross profit in 2024, profitability remains a concern.

Balance Sheet

The company shows a negative stockholders' equity position since 2020, indicating potential solvency issues. The debt-to-equity ratio is not calculable due to negative equity, but total debt has increased significantly, raising leverage concerns. Total liabilities have grown, impacting financial stability.

Cash Flow

Operating cash flow remains negative, with no positive free cash flow reported in the past years. While financing cash flow has been positive, it primarily supports operating activities, not growth. The negative free cash flow to net income ratio indicates cash flow challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.29M	1.60M	1.67M	2.05M	2.10M
	Gross Profit
1.02M	662.00K	983.00K	1.22M	1.47M
	EBIT
0.00	-11.42M	-9.44M	-8.60M	-9.09M
	EBITDA
-11.97M	-13.96M	-7.18M	-6.64M	-8.76M
	Net Income Common Stockholders
-15.40M	-15.66M	-11.30M	-8.72M	-8.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.99M	2.95M	8.41M	8.89M	5.81M
	Total Assets
5.32M	5.21M	12.00M	11.55M	8.16M
	Total Debt
14.93M	8.56M	6.64M	582.00K	667.00K
	Net Debt
11.94M	5.61M	-1.77M	-8.31M	-5.14M
	Total Liabilities
32.87M	21.76M	14.52M	7.47M	8.83M
	Stockholders Equity
-27.55M	-16.55M	-2.52M	4.08M	-669.00K
Cash Flow		Free Cash Flow
-8.85M	-10.91M	-9.96M	-9.18M	-639.00K
	Operating Cash Flow
-8.82M	-10.72M	-9.93M	-8.70M	-324.00K
	Investing Cash Flow
-27.00K	-185.00K	-33.00K	-325.00K	-297.00K
	Financing Cash Flow
8.88M	5.44M	9.48M	12.16M	5.18M

Spectral Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EDT, the sentiment is Positive. The current price of 0.87 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.75, and above the 200-day MA of 0.62, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 69.21 is Neutral, neither overbought nor oversold. The STOCH value of 77.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EDT.

Spectral Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	71 Outperform	C$85.48M	13.30	11.27%	―	-3.82%	-50.36%
EDT	54 Neutral	$230.94M	―	80.28%	―	43.05%	2.14%
PRN	54 Neutral	C$205.77M	―	-59.43%	―	51.21%	15.33%
MDNA	53 Neutral	C$74.30M	―	-149.09%	―	―	-67.03%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
EBM	44 Neutral	C$33.07M	―		―	-2.84%	16.88%
ARCH	26 Underperform	C$110.90M	―	90.17%	―	―	-78.59%

Spectral Medical Corporate Events

Spectral Medical Completes Tigris Trial Enrollment and Secures Funding for PMX Commercialization

Spectral Medical has completed enrollment for its Phase III Tigris trial, which evaluates PMX for endotoxic septic shock, with results expected in August 2025. The company has secured up to US$10 million in funding from Vantive to support PMX commercialization, positioning Spectral closer to potential U.S. FDA approval and market launch, which could significantly impact its operations and market presence.

Spark’s Take on TSE:EDT Stock

According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.

The overall stock score for Spectral Medical is driven by significant financial challenges and weak valuation metrics. However, positive technical momentum and recent corporate developments in clinical trials and financing provide some optimism. Yet, the financial instability and ongoing inability to achieve profitability weigh heavily on the stock’s outlook.

To see Spark’s full report on TSE:EDT stock, click here.

Spectral Medical Secures $10 Million Non-Dilutive Financing for PMX Commercialization

Spectral Medical Inc. has secured a non-dilutive financing agreement of up to $10 million with Vantive US Healthcare LLC to support the commercialization of its blood filtration therapy, Toraymyxin™ (PMX). This funding is expected to fully support Spectral’s path to commercialization, including key milestones such as the release of topline results and U.S. FDA submission. The agreement signifies a strong partnership with Vantive, providing Spectral with financial stability and confidence in advancing PMX through regulatory phases.

Spark’s Take on TSE:EDT Stock

According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.

Spectral Medical’s stock score reflects significant financial challenges, with persistent losses and negative cash flows raising concerns about financial stability. However, recent corporate developments, including progress in a pivotal clinical trial, provide potential upside. Technical analysis suggests positive momentum, though valuation metrics are weak due to a lack of profitability. Overall, while there are promising clinical advancements, the financial and valuation concerns weigh heavily on the stock’s outlook.

To see Spark’s full report on TSE:EDT stock, click here.

Spectral Medical Completes Enrollment for Phase 3 Tigris Trial

Spectral Medical has completed patient enrollment for its Tigris trial, a Phase 3 study evaluating the use of Polymyxin B Hemoperfusion (PMX) in treating endotoxic septic shock. With 157 patients enrolled, the company anticipates releasing topline results in August 2025. This milestone is crucial for Spectral’s regulatory path towards potential PMX approval, with plans to submit clinical results to the FDA by October 2025. The company is also finalizing non-dilutive financing to support PMX commercialization, highlighting its commitment to advancing its regulatory and commercialization efforts.

Spark’s Take on TSE:EDT Stock

According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.

Spectral Medical’s stock score reflects significant financial challenges, with persistent losses and negative cash flows raising concerns about financial stability. However, recent corporate developments, including progress in a pivotal clinical trial, provide potential upside. Technical analysis suggests positive momentum, though valuation metrics are weak due to a lack of profitability. Overall, while there are promising clinical advancements, the financial and valuation concerns weigh heavily on the stock’s outlook.

To see Spark’s full report on TSE:EDT stock, click here.

Spectral Medical Nears Completion of Key Clinical Trial for Sepsis Treatment

Spectral Medical announced its financial results for the fourth quarter and fiscal year 2024, highlighting significant clinical and operational progress. The company is nearing full enrollment in its Phase III Tigris trial, which evaluates PMX for endotoxic septic shock, and is working towards FDA submission. Despite challenges such as Hurricane Helene impacting the medical supply chain, enrollment has been robust, with 154 patients enrolled to date. Spectral is also collaborating with Vantive on commercialization plans, anticipating a positive trial outcome and preparing for PMX’s market launch. The completion of the Tigris study and the PrisMax sub-study are key milestones that could enhance Spectral’s industry positioning and stakeholder value.

Spectral Medical Nears Completion of Phase 3 Tigris Trial for Sepsis Treatment

Spectral Medical Inc. has announced an update on its Tigris trial, a Phase 3 study evaluating the use of Polymyxin B Hemoperfusion (PMX) for treating endotoxemia and septic shock. With 152 patients enrolled, the trial is nearing its target of 150 evaluable patients, expected to be reached by the end of March 2025. The completion of this trial is crucial for PMX’s regulatory review, particularly concerning safety and secondary analyses, which could significantly impact Spectral’s market positioning and stakeholder interests.